In an attempt to identify druggable targets in these lesions, we undertook an in-depth analysis of the mutational profiles of the primary and metastatic tumor tissues, which revealed a novel SETD2 mutation whose molecular effects were documented by in vitro studies. The gene discussed is SETD2; the disease is metastatic neoplasm.